A long-acting analogue of LH-
When luteinizing hormone-releasing hormone (LH-RH) and its analogues are administered to a variety of experimental animals, they release luteinizing hormone (LH) and follicle stimulating hormone (FSH) and an effective induction of ovulation results (Arimura et al., 1971; Rippel et al., 1973; Yamazaki et al., 1978a) . Paradoxically, these peptides also block progesterone secretion, which, in turn, prevents or terminates pregnancy (Casper and Yen, Bex and Corbin, 1979; Jones and Hsueh, 1980) .
We have compared the effectiveness of these peptides in inducing ovulation in the rat by various routes of administration including subcutaneous, intravenous, intraperitoneal, intramuscular, intravaginal, intrarectal, intranasal, intragastric, and sublingual. Parenteral administrations were most effective, although intravaginal, intrarectal, and intranasal routes also showed some effect (Yamazaki et al., 1977; Yamazaki, 1979) . On the other hand, the peptides were found to be more effective in terminating pregnancy in rats when they were administered intravaginally rather than subcutaneously (Yamazaki, 1982) . This difference in effectiveness was thought to be due to differences in the duration of effective peptide blood concentrations, which were much longer-sustained after vaginal than after subcutaneous administration.
In the present study, further data were added to the previously described rough estimation of the pregnancy-terminating effectiveness of an LH-RH analogue, desGly10-[D-Leu6]-LH-RH-ethylamide (TAP-144), administered subcutaneously and intravaginally on day 9 of pregnancy in rats (Yamazaki, 1982) . In addition, the pregnancy-terminating activities of this analogue by these two routes were compared with those following intrarectal and intranasal administrations.
Materials
and Methods
Animals.
The adult female rats used were as described previously (Yamazaki, 1982) . Daily vaginal smears were examined in the morning.
Only those rats regularly exhibiting two or more consecutive 4-day estrous cycles were caged with fertile males on the evening of proestrus.
The next morning, if sperm was present in the vagina, was designated day O of pregnancy (Day O).
Peptide
Used.
TAP-144 (lot 5-2) and thyrotrophin-releasing hormone (TRH) were synthesized in our Chemistry Laboratories (Fujino et al., 1974; Hatanaka et al., 1974 Effect of LH-RH Analogue on Ovariectomized-Progesterone-Treated Rats. Pregnant rats were bilaterally ovariectomized on Day 7 under ether anesthesia and the number of implantation sites in the uterus were counted. Their pregnancy was maintained by daily subcutaneous administration of 3 mg/0.2 ml sesame oil/100g body weight of progesterone from immediately after the operation through Day 13. TAP-144, 1, 10, and 100 g body weight, was administered vaginally twice on Day 9. Autopsy was performed on Day 14.
Statistical Analysis. A 50% effective dose (ED50) value of the peptide in terminating pregnancy by each route was calculated using probit analysis (Finney, 1952) . Potency ratios among the routes of administration were calculated by the parallel line assay (Sakuma, 1964 Previous finding from our laboratory and that of others showed that the critical period during which LH is essential for maintaining viable fetuses is from Day 7 to 11 (Morishige and Rothchild, 1974; Nishi et al., 1976; Bex and Corbin, 1981; Yamazaki, 1982) . Day 9 was the most sensitive for pregnancy-interference with TAP-144. Thus, in the present study, the pregnancyterminating effectiveness of this peptide by various routes of administration on Day 9 was compared.
The results of the effectiveness for the subcutaneous and vaginal routes were essentially the same as the qualitative estimations reported previously (Yamazaki, 1982) . A single dose of TAP-144 on Day 9 by the vaginal route proved to be much more effective in terminating pregnancy than single dosing by the subcutaneous route.
However, when the peptide was administered twice a day, the effectiveness was markedly increased by both routes; the rate of increase in effectiveness being 2,240 timesgreater by the subcutaneous route than by the vaginal route. Thus, twice-a-day dosing obliterated the difference in effective dose observed by the single dosing.
We had found that the serum concentration of TAP-144 after vaginal administration was lowe but much longer-sustained than that after subcutaneous administration (Yamazaki and Okada, 1980) . Furthermore, the paradoxical progesterone secretion blocking effect of LH-RH and its analogues is known to be manifested by direct action on the ovaries (Jones and Hsueh, 1980) , in addition to action through pituitarygonadotrophin secretion. Thus, it is concluded that, for pregnancy termination, the prolonged duration of an effective concentration of TAP-144 is more important than a transient high concentration.
On the other hand, a single subcutaneous administration of TAP-144 was 7.6 times more effective than vaginal administration in inducing ovulation in rats (Yamazaki, 1979) . Ovulation is induced by LH released from the pituitary by TAP-144. After subcutaneous administration of the peptide, the release of LH into the blood lasted for 120-180 min (Yamazaki et al., 1978b) sufficient for the induction of ovulation (Everett and Sawyer, 1953) . Therefore, it may be concluded that the discrepancy between the relative effectiveness of the peptide in terminating pregnancy and in inducing ovulation by both routes is due to a difference in dependency on the duration of the peptide in the blood. When rats weregiven a single dose, the ED50 value of LH-RH for inducing ovulation by the rectal route was 2-4 times larger than that by the vaginal route (Yamazaki et al., 1977) , while the value of TAP-144 for terminating pregnancy by the rectal route was comparable to that by the subcutaneous route and was 1,221 times larger than that by the vaginal route. When TAP-144 was administered twice, the ED50 value for terminating pregnancy by the rectal route was about 200 times larger than that by the vaginal route which was comparable to the subcutaneous route. These findings suggested that the duration of TAP-144 level in blood after administration by the rectal route is between those after administration by the vaginal and subcutaneous routes.
When rats were given a single dose of TAP-144 by the nasal route, the ED50 value for inducing ovulation was about 80 times larger than that by the vaginal route (Yamazaki, 1979) , while the value for terminating pregnancy was 2,000 times or more larger than that by the vaginal route. This finding suggests that the duration of TAP-144 level in blood after administration by the nasal route is shorter than that after administration by the vaginal route. inducing effectiveness (Okada et al ., 1982) . It was also reported that the addition of a surfactant to insulin administered rectally enhanced the effect of the latter (Shichiri et al., 1978) . In the present study , the addition of the surfactant markedly enhanced the pregnancy terminating effectiveness of TAP-144 administered nasally but not rectally. The reason for the difference between the pregnancy termination enhancing efficacy of the surfactant in the rectal and nasal mucosa remains unexplained , but intricate factors involved in peptide absorption from the mucous membranes such as differences in tissue and cell structures , in diffusibility and permeability of the peptides , and in capillary distribution might be responsible. When rats are given TAP-144 twice a day on Day 9 by subcutaneous and vaginal routes, serum concentrations of progesterone and estrogen drop sharply (Yamazaki , 1982) . This finding suggests that TAP-144 acts on the ovaries directly or indirectly to suppress the secretion of these steroids, essential to the maintenance of pregnancy. Thus, it may be possible that progesterone treatment can reverse the pregnancy interfering effect of TAP-144. In addition, TAP-144 might directly act on the uterus to reduce its responsiveness to progesterone, since the direct effect of a LH-RH agonist on the uterus is reported to reduce responsiveness to estrogen (Pedroza et al., 1980) . This mechanism, if present, may explain, at least in part, the great effectiveness of TAP-144 by the vaginal route, because, on the basis of anatomical contiguity and vascular distribution, it is possible that higher concentrations of TAP-144 could reach the uterus by the intravaginal than by other routes. To confirm these points, pregnant rats were ovariectomized on Day 7 and 
